Best Niche Antibody-based Biologics

RANK (Fc-Fusion)

RANK (Fc-Fusion)

Part No. P7032F
Regular price
$ 499.00
Sale price
$ 499.00
Regular price
Out of Stock
Unit price
per 

RANK (for receptor activator of NF-kappaB), a type I membrane protein, is a member of the TNFR superfamily and plays important roles in bone physiology as well as in regulation of the interactions between dendritic cells and T lymphocytes.

Interacting protein(s): RANKL
Related products: TNF-Receptor Superfamily

Read all details below including Quick Specs.

** Please note: For orders over 1 mg, please inquire here

Quick Specs

Species: Human
Catalog No.: P7032F
Synonym: TNFRSF11A, CD265, RANK, TRANCER
Tag: mouse IgG2a-Fc
GenBank Accession: NM_003839
SwissPro Accession: Q9Y6Q6
Construction: h.RANK (I30-P212)-m.IgG-Fc
Expression Host: 293T
MoW (calculated): 47,212 daltons
MW (SDS-PAGE): 50 Kd
Abs 0.1% (= 1 mg/ml): 1.26
Purity: 95 %

Description

RANK (for receptor activator of NF-kappaB), a type I membrane protein, is a member of the TNFR superfamily and plays important roles in bone physiology as well as in regulation of the interactions between dendritic cells and T lymphocytes. RANK is ubiquitously expressed at high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. Ligand of RANK, RANKL, also called osteoclast differentiation factor (ODF), binds to both RANK on cell surface and the soluble decoy receptor osteoprotegerin (OPG).

The balance between the surface RANK-mediated osteoclastogenesis and the decoy OPG-mediated inhibition fine tunes the activity of osteoclasts that ultimately controls the bone remodeling. Defects in RANK are the cause of a variety of osteo-disorders including familial expansile osteolysis (FEO); Paget disease of bone type 2 (PDB2) and osteopetrosis autosomal recessive type 7 (OPTB7). OPTB7 also called osteoclast-poor osteopetrosis with hypogammaglobulinemia. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone.

The disorder occurs in two forms: a severe autosomal recessive form with an infancy onset, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.

Amino Acid Sequence.

References

1. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. Nature 390:175-179 (1997)

2. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., Higashio K. Biochem. Biophys. Res. Commun. 253:395-400 (1998)

3. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis."

4. Hughes A.E., Ralston S.H., Marken J., Bell C., MacPherson H., Wallace R.G.H., van Hul W., Whyte M.P., Nakatsuka K., Hovy L., Anderson D.M. Nat. Genet. 24:45-48 (2000)

5. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Guerrini M.M., Sobacchi C., Cassani B., Abinun M., Kilic S.S., Pangrazio A., Moratto D., Mazzolari E., Clayton-Smith J., Orchard P., Coxon F.P., Helfrich M.H., Crockett J.C., Mellis D., Vellodi A., Tezcan I., Notarangelo L.D., Rogers M.J. expand/collapse author list Frattini A. Am. J. Hum. Genet. 83:64-76 (2008)